Phase 1's primary outcome was safety assessment.[1] A first phase 1 study was conducted on 56 healthy volunteers who were at the age of 18–50.[2][35][36][5] Last injections of the second doses occurred on 4 March 2021.[6] A second phase 1 study was conducted on 32 volunteers aged 51-75 years.[6] First injections occurred on March 15 and last injections on April 9.[6]